Open Access Article
This Open Access Article is licensed under a
Creative Commons Attribution 3.0 Unported Licence

Synthesis of N-CD3 aryl amines via iron-catalysed site-selective aromatic C–H amination

Meng-Meng Ren , Yin Yang and Fei Wang *
State Key Laboratory of Elemento-Organic Chemistry, Frontiers Science Center for New Organic Matter, College of Chemistry, Nankai University, Weijin Rd. 94, Tianjin 300071, China. E-mail: fwang235@nankai.edu.cn

Received 24th May 2025 , Accepted 16th September 2025

First published on 22nd September 2025


Abstract

The strategic incorporation of deuterium atoms into pharmaceutical compounds can profoundly influence their pharmacokinetic profiles and metabolic stability. This is particularly relevant for the ubiquitous N-methyl motif in bioactive molecules, where metabolic oxidation of the methyl group often represents a major pathway. Despite this potential, synthetic methods for the direct introduction of the N-CD3 group through C–H functionalization remain elusive. We report herein an iron-catalysed protocol for the synthesis of N-CD3 anilines through site-selective aromatic C–H amination. An iron-aminyl radical is proposed as the key intermediate that facilitates site-selective homolytic aromatic substitution (HAS) through chelating with basic functional groups, including amides, urea and carbamate. The resulting ortho-amino products serve as versatile synthetic intermediates for valuable heterocycles. Importantly, the Weinreb amide proves effective as a directing group, offering the advantage of transforming into diverse carbonyl molecules.


Introduction

While the substitution of hydrogen with deuterium represents the smallest possible structural modification in organic molecules, its impact on drug properties can be profound.1 As demonstrated by deutetrabenazine, the first FDA-approved deuterated drug, its superior pharmacokinetic profile over its non-deuterated counterpart enables reduced dose and dosing frequency.2 Consequently, synthetic methods for deuterium incorporation—whether during target molecule construction or via late-stage H/D exchange—have garnered increasing attention.3 This is especially pertinent for N-methyl (N-CH3) groups, which are ubiquitous in bioactive compounds yet often susceptible to oxidative metabolism.1,4,5 Replacing N-CH3 with N-CD3 offers a compelling strategy to attenuate such metabolic liabilities (Fig. 1A).6 Thus, the direct incorporation of the N-CD3 motif into organic molecules is highly demanded.
image file: d5sc03780h-f1.tif
Fig. 1 Context of this work. SET = single electron transfer, CT = charge transfer, EDG = electron-donating group.

The prevalence of aryl amines in pharmaceuticals underscores the importance of developing efficient methods for their synthesis.7 Direct amination of aromatic C–H bonds represents an attractive strategy, combining the ready availability of arene substrates with the step-/atom-economy inherent to C–H functionalization processes.8 While significant progress has been achieved in this field, limited success has been achieved for the direct introduction of an NHR group (R = alkyl) to access secondary aryl amines (Fig. 1B).9,10 The pioneering works from Minisci and co-workers established the feasibility of NHR amination of arenes via the N-alkyl aminium radical cation, albeit under harsh conditions with low yields and limited substrate scope.11 Recently, significant advances have been made by Falck, Kürti, Ess, Nicewicz, Leonori, Morandi, Hashmi and Phipps through developing new catalytic systems and novel aminating reagents (Fig. 1B).12–14 For instance, Falck and co-workers developed dirhodium- and copper-catalysed systems using NH(alkyl)-O-(sulfonyl)hydroxylamines.12a,c Morandi reported an iron-catalysed variant employing NH(methyl)-O-(sulfonyl)hydroxylamines·HOTf.12e Hashmi presented a metal-free system using NH(alkyl)-O-(sulfonyl)hydroxylamines, in which a charge transfer (CT) complex between the arene substrate and hydroxylamine reagent was suggested.12f Photoredox approaches have also emerged. Nicewicz and co-workers reported a photocatalytic amination of arenes with primary amines, wherein oxidation of an arene to an arene radical cation was proposed.12b Alternatively, the group of Leonori employed alkyl amines and N-chlorosuccinimide (NCS) to generate N-chloroalkylamines in situ, which served as effective aminating reagents through photochemical generation of nitrogen centered radicals (NCRs).12c However, these reactions work ineffectively for electron-deficient arenes and/or suffer from poor regioselectivity. Phipps and co-workers deployed the non-covalent interaction between the N-alkyl aminium radical cation and anionic arene substrates to enable highly ortho-selective amination of sulfamate derived from aniline.15a More recently, they achieved an ortho-selective amination of arene carboxylic acids via an intramolecular rearrangement of acyl O-hydroxylamines.15c Despite these important contributions, there is still a necessity for the development of complementary methods, which is applicable to readily available arene substrates and exerts excellent regioselectivity. Moreover, this field still lacks general methods for site-selective NH-CD3 amination of arene C–H bonds—a significant gap given the growing importance of deuterated pharmaceuticals.

With our continuous interest in radical-mediated selective amination reactions,16 we present here an iron-catalysed method for direct access to N-CD3 anilines through site-selective aromatic C–H functionalization (Fig. 1C). An iron-aminyl radical is invoked as the key intermediate that facilitates the site-selective homolytic aromatic substitution (HAS) via chelating with basic functional groups. Notably, the Weinreb amide proves effective as a directing group, allowing access to other carbonyl functionalities through established protocols. The ortho-amino benzamide products are valuable synthetic building blocks towards pharmacologically relevant heterocycles.

Results and discussion

Reaction development

Our experiments were initiated with the ortho-selective N-CH3 amination of benzamide 1a using NH(CH3)-O-(pivaloyl)hydroxylamines·HOTf as the electrophilic aminating reagent (see the SI for full reaction optimizations).17 No appreciable yield (<1%) was obtained when the reaction was conducted with Fe(OAc)2 as a catalyst in methanol, ethyl acetate or 1,4-dioxane, while the product was afforded in 22% yield using CH2Cl2 as a solvent (Fig. 2, entries 1–4). HFIP proved to be optimal, giving the desired product in 76% yield. The use of FeCl2 or Fe(OTf)2 in replacement of Fe(OAc)2 led to slightly decreased yield, while the reaction is completely shut down using iron(II) phthalocyanine (Fig. 2, entries 5–8). Notably, dihydroquinazolinone side product 2a′ was observed in addition to 2a (see the SI for details). We attribute these results to the involvement of an imine or iminium, generated via deprotonation of the α-C–H bond of an iron-aminyl radical or free NCR18 and the subsequent single electron oxidation, followed by its condensation with 2a (Fig. 2, bottom). Strikingly, higher yield was obtained when using NH(CD3)-O-(pivaloyl)hydroxylamines·HOTf as the aminating reagent under otherwise identical conditions, with no d5-2a′ formed (Fig. 2, entry 9). These results might stem from the attenuated deprotonation of the deuterated NCRs thanks to the deuterium kinetic isotope effect.19 Running the reaction at lower temperature leads to decreased yield with 10% of 1a remaining (Fig. 2, entry 10). While adding one equivalent of water into the reaction mixture did not affect the reaction, high water loading significantly decreased the yield (Fig. 2, entries 11–13). We proposed that water might compete with 1a in coordinating with the iron-aminyl radical, shunting the desired radical addition to arenes. Alternatively, the iron-aminyl radical complex might be destroyed by water through coordination with iron. Slightly decreased yield was observed when the reaction was performed under air, implying its insensitivity to oxygen (Fig. 2, entry 14). Finally, no reaction occurred in the absence of the iron catalyst (Fig. 2, entry 15).
image file: d5sc03780h-f2.tif
Fig. 2 Reaction development. aThe reaction was performed at 0 °C. bWith H2O (1.0 equiv.). cWith H2O (5.0 equiv.). dWith H2O (10.0 equiv.). eUnder air. fOnly ortho-aminated products were formed. The yields were determined by 1H-NMR analysis with CH2Br2 as an internal standard. Isolated yields are shown in parentheses. n.d. = not detected.

Proposed reaction pathway

Building on our previous studies on iron-catalysed primary amination of arene C–H bonds16b–e and related precedents in the literature,20 a proposed reaction pathway is illustrated in Fig. 3A. The reaction begins with single electron transfer between Fe(II) and NH(CD3)-O-(pivaloyl)hydroxylamines·HOTf to afford the key iron-aminyl radical intermediate, along with formation of pivalic acid. Then, substrate chelation takes place to facilitate radical addition and dictate the regioselectivity, generating a σ-complex. Finally, the product was formed as an anilinium triflate, via electron transfer and proton transfer or proton coupled electron transfer, while the Fe(II) catalyst was regenerated.
image file: d5sc03780h-f3.tif
Fig. 3 Proposed reaction pathway and control experiments. (A) The proposed reaction pathway involving an iron-aminyl radical. (B) Control experiments that preclude the involvement of an aminium radical cation. These reactions were analysed by 1H-NMR with CH2Br2 as an internal standard. aOnly ortho-aminated products were formed. Ar* = 4-NO2C6H4.

The involvement of NCR was evidenced by electron paramagnetic resonance (EPR) analysis of the reaction mixture (see the SI for details). The excellent ortho-selectivity suggested against the intermediacy of the free aminium radical cation because the amide anion species is unlikely formed under the present acidic conditions to facilitate the site-selective radical addition via electrostatic interaction.15 In addition, a tertiary amide is a suitable substrate, affording the associated product with excellent site-selectivity (vide infra). Moreover, no 3a was formed when a strong acid, such as TfOH or MsOH, was added into the reaction mixture, assuming the iron-aminyl radical is converted to the aminium radical cation through protonation (Fig. 3B). Meanwhile, using NH(CD3)-O-(sulfonyl)hydroxylamines·HOTf as an aminating reagent, previously proposed to generate an aminium radical cation upon reaction with Fe(II), did not lead to any desired product.12e,15b The lack of reactivity with the aminium radical cation might arise from the electron-deficient character of benzamide. These results highlight the unique reactivity and selectivity of the iron-aminyl radical intermediate, assisted by substrate chelation.

Substrate scope

Efforts were then made to investigate the reaction scope (Fig. 4). The protocol demonstrated excellent compatibility with primary, secondary, and tertiary benzamides, consistently delivering ortho-NHCD3 products in good-to-excellent yields (3a–3d, 62–85%). The Weinreb amide proved particularly valuable, serving both as an effective directing group and as a versatile synthetic handle for subsequent transformations (vide infra). In addition to the exclusive ortho-selectivity, selective amination of the electron-deficient aromatic motif for 3d is noteworthy, underscoring the unique regiochemical control imparted by the iron-aminyl radical. Secondary benzamides derived from diverse primary alkylamines are amenable to this reaction (3e–3j), including biologically relevant substrates like phenylalanine derivatives (3j). Substituted benzamides bearing halide, alkyl or hydroxyl groups all participated effectively in the present amination reaction, affording the desired products in good-to-excellent yields (3k–3q). Notably, the protocol enabled late-stage C–H amination of glibenclamide, an oral hypoglycemic agent for the treatment of diabetes, with the site-selectivity exclusively dictated by amide chelation, overriding the inherent electronic effect of the methoxyl substituent (3r). Naphthalene derivatives exhibited interesting regiochemical outcomes: while 2-naphthalenecarboxamide reacted conventionally (3s, 66%), the 1-isomer showed preferential amination at the C8 position (3t, 70%, C8[thin space (1/6-em)]:[thin space (1/6-em)]C2 > 20[thin space (1/6-em)]:[thin space (1/6-em)]1). The reaction with phenylcarbamate mainly afforded the ortho-aminated product, while the para-product was also observed due to the electron-rich character of the aromatic ring and the non-directed HAS pathway (3u). In contrast, the urea substrate gave an exclusive ortho-selectivity (3v). However, aryl phosphine oxide and sulfoxide could only work for substrates bearing an electron-donating group (3w and 3x), e.g. methoxyl group, possibly due to the decreased electrophilicity and accordingly the reactivity of the proposed Fe-·NHCD3 than that of Fe-·NH2 (see the SI for unsuccessful substrates). In addition, the methodology extended effectively to 2-phenylacetamides, providing direct access to 2-(2-aminophenyl)acetamides that could be cyclized to 2-indolinones under mild acidic conditions (3y–3ae, 65–94%). Both primary and secondary amides performed well, and functionality including boronic esters (3z) and bromides (3ae) remained intact, offering valuable handles for further derivatization. Of note, the reaction is easily to scale-up without diminishing the reaction efficiency and regioselectivity (Fig. 5A, 3c, 3i and 3k).
image file: d5sc03780h-f4.tif
Fig. 4 Substrate scope. Isolated yields, see the SI for details. Only ortho-aminated products were formed except for 3t and 3u.

image file: d5sc03780h-f5.tif
Fig. 5 Gram-scale reaction and product diversification. Isolated yields, see the SI for details.

Product diversification

The versatility of Weinreb amide allowed us to access a variety of carbonyl molecules through convenient nucleophilic substitution reactions (Fig. 5B, see the SI for details). For example, 3c was converted to an ynone product (4) in 70% yield using (phenylethynyl)lithium as a nucleophile. 2-Aminobenzaldehyde (5) was obtained in 80% yield through treatment of 3c with LiAlH4. Other reagents such as BuLi and 2-PyLi are suitable nucleophiles that afford structurally diverse carbonyl products in moderate yields (6 and 7). In addition, the 2-aminobenzamide products were transformed to a number of pharmaceutically relevant heterocycles. For instance, 3k was condensed with aldehydes, generating dihydroquinazolinones (8–10) in good yields; cyclization of 3i with bis(trichloromethyl) carbonate (BTC) took place effectively to give 11 in 95% yield. Finally, 3k was subjected to an SNAr reaction, generating 12 in a yield of 53%.

Conclusions

In conclusion, we have developed an electrophilic N-CD3 aminating reagent, NH(CD3)-O-(pivaloyl)hydroxylamines·HOTf, and demonstrated its utility in iron-catalysed, ortho-selective C–H amination of arenes. This transformation exhibits broad substrate scope, accommodating primary, secondary and tertiary benzamides, phenyl carbamate, phenyl urea and 2-phenylacetamides, while maintaining good yield and regioselectivity for late-stage C–H amination of complex molecules. The unique regiochemical control imparted by an iron-aminyl radical through substrate chelation supersedes the inherent substituent directing effects. Moreover, the amenability of using the Weinreb amide as a directing group enables subsequent product diversification; ortho-amino benzamides are valuable synthetic intermediates to build heterocycles. Current investigations are focused on exploring applications of this electrophilic N-CD3 reagent in other selective transformations.

Author contributions

M.-M. R. conducted all the experiments and characterized all the new compounds. The EPR experiments were performed by Y. Y. with assistance from M.-M. R. M.-M. R. and F. W. designed the experiments and wrote the manuscript.

Conflicts of interest

There are no conflicts to declare.

Data availability

Supplementary information: experimental procedures and analytical data (NMR, HRMS and EPR). See DOI: https://doi.org/10.1039/d5sc03780h.

Acknowledgements

We are grateful for the financial support by the National Natural Science Foundation of China (No. 22101140, 22371143 and 22188101), the Natural Science Foundation of Tianjin (24JCYBJC00300), the Fundamental Research Funds for the Central Universities, Haihe Laboratory of Sustainable Chemical Transformations, Collaborative Innovation Center of Chemical Science and Engineering (Tianjin) and Frontiers Science Center for New Organic Matter at Nankai University.

Notes and references

  1. (a) T. G. Gant, J. Med. Chem., 2014, 57, 3595–3611 CrossRef PubMed; (b) S. Kaur and M. Gupta, Indo Global J. Pharm. Sci., 2017, 1, 555566 Search PubMed; (c) T. Pirali, M. Serafini, S. Cargnin and A. A. Genazzani, J. Med. Chem., 2019, 62, 5276–5297 CrossRef PubMed; (d) T. M. Belete, Drug Des., Dev. Ther., 2022, 16, 3465–3472 CrossRef PubMed; (e) A. K. N. Neelam, V. Durga, A. R. Mulaparthi, E. Puli and P. Badarala, J. Pharma Insight Res., 2023, 1, 17–23 Search PubMed; (f) R. M. C. Di Martino, B. D. Maxwell and T. Pirali, Nat. Rev. Drug Discovery, 2023, 22, 562–584 CrossRef PubMed; (g) W. W. Wood, J. Med. Chem., 2024, 67, 16991–16999 CrossRef PubMed.
  2. R. B. Raffa, J. V. Pergolizzi and R. Taylor, J. Pharm. Pharmacol., 2018, 9, 440–446 CrossRef.
  3. (a) J. Atzrodt, V. Derdau, T. Fey and J. Zimmermann, Angew. Chem., Int. Ed., 2007, 46, 7744–7765 CrossRef PubMed; (b) J. Atzrodt, V. Derdau, W. J. Kerr and M. Reid, Angew. Chem., Int. Ed., 2018, 57, 3022–3047 CrossRef CAS; (c) R. Zhou, L. Ma, X. Yang and J. Cao, Org. Chem. Front., 2021, 8, 426–444 RSC; (d) S. Kopf, F. Bourriquen, W. Li, H. Neumann, K. Junge and M. Beller, Chem. Rev., 2022, 122, 6634–6718 CrossRef CAS PubMed; (e) G. Prakash, N. Paul, G. A. Oliver, D. B. Werz and D. Maiti, Chem. Soc. Rev., 2022, 51, 3123–3163 RSC; (f) N. Li, Y. T. Li, X. P. Wu, C. J. Zhu and J. Xie, Chem. Soc. Rev., 2022, 51, 6291–6306 RSC; (g) P. L. Norcott, Chem. Commun., 2022, 58, 2944–2953 RSC; (h) H. Li, M. Shabbir and A. Lei, Chin. J. Chem., 2024, 42, 1145–1156 CrossRef CAS.
  4. J. Jiang, X. Pang, L. Li, X. Dai, X. Diao, X. Chen, D. Zhong, Y. Wang and Y. Chen, Drug Des., Dev. Ther., 2016, 10, 2181–2191 CrossRef CAS PubMed.
  5. (a) B. Meunier, S. P. de Visser and S. Shaik, Chem. Rev., 2004, 104, 3947–3980 CrossRef CAS PubMed; (b) S. Shaik, D. Kumar, S. P. de Visser, A. Altun and W. Thiel, Chem. Rev., 2005, 105, 2279–2328 CrossRef CAS; (c) S. Shaik, S. Cohen, Y. Wang, H. Chen, D. Kumar and W. Thiel, Chem. Rev., 2010, 110, 949–1017 CrossRef; (d) M. A. Cerny and R. P. Hanzlik, J. Am. Chem. Soc., 2006, 128, 3346–3354 CrossRef PubMed; (e) D. Li, Y. Wang, C. Yang and K. Han, Dalton Trans., 2009, 2009, 291–297 RSC; (f) C. Wu, S. Wang, D. Sun, J. Chen, W. Ji, Y. Wang, W. Nam and B. Wang, J. Am. Chem. Soc., 2025, 147, 11432–11445 CrossRef PubMed.
  6. (a) L. R. Hall and R. P. Hanzlik, J. Biol. Chem., 1990, 265, 12349–12355 CrossRef PubMed; (b) E. Baciocchi, O. Lanzalunga, A. Lapi and L. Manduchi, J. Am. Chem. Soc., 1998, 120, 5783–5787 CrossRef; (c) Y. Goto, Y. Watanabe, S. Fukuzumi, J. P. Jones and J. P. Dinnocenzo, J. Am. Chem. Soc., 1998, 120, 10762–10763 CrossRef; (d) T. S. Dowers, D. A. Rock, D. A. Rock and J. P. Jones, J. Am. Chem. Soc., 2004, 126, 8868–8869 CrossRef PubMed; (e) C. Li, W. Wu, D. Kumar and S. Shaik, J. Am. Chem. Soc., 2006, 128, 394–395 CrossRef PubMed; (f) Y. Wang, D. Kumar, C. Yang, K. Han and S. Shaik, J. Phys. Chem. B, 2007, 111, 7700–7710 CrossRef PubMed; (g) C. Li, W. Wu, K.-B. Cho and S. Shaik, Chem.–Eur. J., 2009, 15, 8492–8503 CrossRef PubMed; (h) A. Barbieri, M. De Gennaro, S. Di Stefano, O. Lanzalunga, A. Lapi, M. Mazzonna, G. Olivo and B. Ticconi, Chem. Commun., 2015, 51, 5032–5035 RSC.
  7. (a) S. A. Lawrence, Amines: Synthesis, Properties and Applications, Cambridge University Press, Cambridge, 2004 Search PubMed; (b) J. F. Hartwig, S. Shekhar, Q. Shen and F. Barrius-Landeros, Synthesis of anilines, in The chemistry of anilines, John Wiley & Sons, New York, 2007 Search PubMed; (c) A. Ricci, ed. Amino Group Chemistry: From Synthesis to the Life Sciences, Wiley-VCH, Weinheim, 2008 Search PubMed; (d) P. F. Vogt and J. J. Gerulis, Aromatic amines, in Ullmann's Encyclopedia of Industrial Chemistry, Wiley-VCH, Weinheim, 2011 Search PubMed.
  8. (a) J. Jiao, K. Murakami and K. Itami, ACS Catal., 2016, 6, 610–633 CrossRef; (b) Y. Park, Y. Kim and S. Chang, Chem. Rev., 2017, 117, 9247–9301 CrossRef; (c) Y. Zhao and W. Xia, Chem. Soc. Rev., 2018, 47, 2591–2608 RSC; (d) I. P. Beletskaya and A. D. Averin, Russ. Chem. Rev., 2021, 90, 1359–1396 CrossRef; (e) L. G. O'Neil and J. F. Bower, Angew. Chem., Int. Ed., 2021, 60, 25640–25666 CrossRef PubMed; (f) C. Pratley, S. Fenner and J. A. Murphy, Chem. Rev., 2022, 122, 8181–8260 CrossRef PubMed; (g) L. Van Emelen, M. Henrion, R. Lemmens and D. De Vos, Catal. Sci. Technol., 2022, 12, 360–389 RSC.
  9. (a) L. D. Tran, J. Roane and O. Daugulis, Angew. Chem., Int. Ed., 2013, 52, 6043–6046 CrossRef PubMed; (b) N. T.-T. Tran, Q. H. Tran and T. Truong, J. Catal., 2014, 320, 9–15 CrossRef; (c) J. J. Farndon, X. Ma and J. F. Bower, J. Am. Chem. Soc., 2017, 139, 14005–14008 CrossRef PubMed; (d) A. K. Hajra, P. Ghosh, C. Roy, M. Kundu, S. Ghosh and S. Das, Org. Biomol. Chem., 2024, 22, 6617–6630 RSC.
  10. (a) E. J. Yoo, S. Ma, T.-S. Mei, K. S. L. Chan and J.-Q. Yu, J. Am. Chem. Soc., 2011, 133, 7652–7655 CrossRef PubMed; (b) P. Wang, G.-C. Li, P. Jain, M. E. Farmer, J. He, P.-X. Shen and J.-Q. Yu, J. Am. Chem. Soc., 2016, 138, 14092–14099 CrossRef; (c) N. Tezuka, K. Shimojo, K. Hirano, S. Komagawa, K. Yoshida, C. Wang, K. Miyamoto, T. Saito, R. Takita and M. Uchiyama, J. Am. Chem. Soc., 2016, 138, 9166–9171 CrossRef; (d) H. Kim, J. Heo, J. Kim, M.-H. Baik and S. Chang, J. Am. Chem. Soc., 2018, 140, 14350–14356 CrossRef; (e) L. Yu, C. Yang, Y. Yu, D. Liu, L. Hu, Y. Xiao, Z.-N. Song and Z. Tan, Org. Lett., 2019, 21, 5634–5638 CrossRef; (f) R. R. Anugu, S. Munnuri and J. R. Falck, J. Am. Chem. Soc., 2020, 142, 5266–5271 CrossRef.
  11. (a) Y. L. Chow, W. C. Danen, S. F. Nelsen and D. H. Rosenblatt, Chem. Rev., 1978, 78, 243–274 CrossRef; (b) F. Minisci, Synthesis, 1973, 1–24 Search PubMed.
  12. (a) M. P. Paudyal, A. M. Adebesin, S. R. Burt, D. H. Ess, Z. Ma, L. Kürti and J. R. Falck, Science, 2016, 353, 1144–1147 CrossRef; (b) K. A. Margrey, A. Levens and D. A. Nicewicz, Angew. Chem., Int. Ed., 2017, 56, 15644–15648 CrossRef PubMed; (c) S. Munnuri, R. R. Anugu and J. R. Falck, Org. Lett., 2019, 21, 1926–1929 CrossRef PubMed; (d) A. Ruffoni, F. Juliá, T. D. Svejstrup, A. J. McMillan, J. J. Douglas and D. Leonori, Nat. Chem., 2019, 11, 426–433 CrossRef CAS PubMed; (e) E. Falk, V. C. M. Gasser and B. Morandi, Org. Lett., 2021, 23, 1422–1426 CrossRef CAS PubMed; (f) T. Wang, M. Hoffmann, A. Dreuw, E. Hasagić, C. Hu, P. M. Stein, S. Witzel, H. Shi, Y. Yang, M. Rudolph, F. Stuck, F. Rominger, M. Kerscher, P. Comba and A. S. K. Hashmi, Adv. Synth. Catal., 2021, 363, 2783–2795 CrossRef CAS; (g) V. Lemmens, K. Janssens, J. Gascon and D. E. De Vos, Green Chem., 2023, 25, 5113–5122 RSC.
  13. (a) G. B. Boursalian, M.-Y. Ngai, K. N. Hojczyk and T. Ritter, J. Am. Chem. Soc., 2013, 135, 13278–13281 CrossRef CAS; (b) K. Foo, E. Sella, I. Thome, M. D. Eastgate and P. S. Baran, J. Am. Chem. Soc., 2014, 136, 5279–5282 CrossRef CAS PubMed; (c) L. J. Allen and M. S. Sanford, J. Am. Chem. Soc., 2014, 136, 5607–5610 CrossRef CAS PubMed; (d) T. Kawakami, K. Murakami and K. Itami, J. Am. Chem. Soc., 2015, 137, 2460–2463 CrossRef CAS; (e) T. W. Greulich and A. Studer, Org. Lett., 2015, 17, 254–257 CrossRef CAS PubMed; (f) S. Das and B. König, Chem.–Eur. J., 2017, 23, 18161–18165 CrossRef CAS PubMed; (g) C. B. Tripathi and T. Ooi, Chem. Sci., 2017, 8, 5622–5627 RSC; (h) E. Ito, K. Murakami and K. Itami, Chem, 2017, 2, 383–392 CrossRef CAS; (i) L.-B. Niu, H. Yi and A. Lei, Nat. Commun., 2017, 8, 14226 CrossRef; (j) H. Huang, Z. M. Strater, M. Rauch, J. Shee, T. J. Sisto, C. Nuckolls and T. H. Lambert, Angew. Chem., Int. Ed., 2019, 58, 13318–13322 CrossRef CAS; (k) X. Hu, G. Zhang, L. Nie, T. Kong and A. Lei, Nat. Commun., 2019, 10, 5467 CrossRef PubMed; (l) J.-H. Wang, T. Lei, X.-L. Nan, H.-L. Wu, X.-B. Li, B. Chen, C.-H. Tung and L.-Z. Wu, Org. Lett., 2019, 21, 5581–5585 CrossRef CAS; (m) L. Zhang, L. Liardet, J. Luo, D. Ren, M. Graetzel and X. Hu, Nat. Catal., 2019, 2, 366–373 CrossRef CAS PubMed; (n) H. Huang and T. H. Lambert, Angew. Chem., Int. Ed., 2021, 60, 11163–11167 CrossRef CAS; (o) K. Targos, O. P. Williams and Z. K. Wickens, J. Am. Chem. Soc., 2021, 143, 4125–4132 CrossRef CAS PubMed; (p) M. R. Lasky, E.-C. Liu, M. S. Remy and M. S. Sanford, J. Am. Chem. Soc., 2024, 146, 14799–14806 CrossRef CAS.
  14. (a) T. Morofuji, A. Shimizu and J.-i. Yoshida, J. Am. Chem. Soc., 2013, 135, 5000–5003 CrossRef CAS PubMed; (b) N. A. Romero, K. A. Margrey, N. E. Tay and D. A. Nicewicz, Science, 2015, 349, 1326–1330 CrossRef CAS PubMed; (c) Y.-W. Zheng, B. Chen, P. Ye, K. Feng, W. Wang, Q.-Y. Meng, L.-Z. Wu and C.-H. Tung, J. Am. Chem. Soc., 2016, 138, 10080–10083 CrossRef CAS PubMed; (d) G. B. Boursalian, W. S. Ham, A. R. Mazzotti and T. Ritter, Nat. Chem., 2016, 8, 810–815 CrossRef CAS PubMed; (e) L. Legnani, G. P. Cerai and B. Morandi, ACS Catal., 2016, 6, 8162–8165 CrossRef CAS; (f) J. Liu, K. Wu, T. Shen, Y. Liang, M. Zou, Y. Zhu, X. Li, X. Li and N. Jiao, Chem.–Eur. J., 2017, 23, 563–567 CrossRef CAS; (g) S. C. Cosgrove, J. M. C. Plane and S. P. Marsden, Chem. Sci., 2018, 9, 6647–6652 RSC; (h) E. M. D'Amato, J. Börgel and T. Ritter, Chem. Sci., 2019, 10, 2424–2428 RSC; (i) S. L. Rössler, B. J. Jelier, P. F. Tripet, A. Shemet, G. Jeschke, A. Togni and E. M. Carreira, Angew. Chem., Int. Ed., 2019, 58, 526–531 CrossRef; (j) J. Hillenbrand, W. S. Ham and T. Ritter, Org. Lett., 2019, 21, 5363–5367 CrossRef CAS PubMed; (k) W. S. Ham, J. Hillenbrand, J. Jacq, C. Genicot and T. Ritter, Angew. Chem., Int. Ed., 2019, 58, 532–536 CrossRef CAS; (l) Y. Y. See and M. S. Sanford, Org. Lett., 2020, 22, 2931–2934 CrossRef CAS; (m) M. R. Lasky, T. K. Salvador, S. Mukhopadhyay, M. S. Remy, T. P. Vaid and M. S. Sanford, Angew. Chem., Int. Ed., 2022, 61, e202208741 CrossRef CAS; (n) N. E. Behnke, Y.-D. Kwon, M. T. Davenport, D. H. Ess and L. Kürti, J. Org. Chem., 2023, 88, 11847–11854 CrossRef CAS; (o) Q. Lv, Z. Hu, Y. Zhang, Z. Zhang and H. Lei, J. Am. Chem. Soc., 2024, 146, 1735–1741 CrossRef CAS; (p) C. Pratley, S. Fenner and J. A. Murphy, Org. Lett., 2024, 26, 1287–1292 CrossRef CAS; (q) E. M. Alvarez, G. Stewart, M. Ullah, R. Lalisse, O. Gutierrez and C. A. Malapit, J. Am. Chem. Soc., 2024, 146, 3591–3597 CrossRef CAS.
  15. (a) J. E. Gillespie, C. Morrill and R. J. Phipps, J. Am. Chem. Soc., 2021, 143, 9355–9360 CrossRef CAS; (b) C. Morrill, J. E. Gillespie and R. J. Phipps, Angew. Chem., Int. Ed., 2022, 61, e202204025 CrossRef CAS; (c) J. E. Gillespie, N. Y. S. Lam and R. J. Phipps, Chem. Sci., 2023, 14, 10103–10111 RSC.
  16. (a) S.-M. Jia, Y.-H. Huang, Z.-L. Wang, F.-X. Fan, B.-H. Fan, H.-X. Sun, H. Wang and F. Wang, J. Am. Chem. Soc., 2022, 144, 16316–16324 CrossRef CAS; (b) C.-R. Ma, G.-W. Huang, H. Xu, Z.-L. Wang, Z.-H. Li, J. Liu, Y. Yang, G. Li, Y. Dang and F. Wang, Nat. Catal., 2024, 7, 636–645 CrossRef CAS; (c) Z.-L. Wang, J.-K. Cheng and F. Wang, Angew. Chem., Int. Ed., 2024, 63, e202412103 CrossRef CAS; (d) F.-X. Fan, H. Xu, S.-X. Tang, Y. Dang and F. Wang, Nat. Commun., 2025, 16, 1471 CrossRef CAS; (e) Q. Wang, J.-K. Cheng, S.-X. Tang, K. N. Houk and F. Wang, Nat. Commun., 2025, 16, 3168 CrossRef CAS PubMed.
  17. E. Falk, S. Makai, T. Delcaillau, L. Gürtler and B. Morandi, Angew. Chem., Int. Ed., 2020, 59, 21064–21071 CrossRef CAS PubMed.
  18. Y. Qin, Q. Zhu, R. Sun, J. M. Ganley, R. R. Knowles and D. G. Nocera, J. Am. Chem. Soc., 2021, 143, 10232–10242 CrossRef CAS.
  19. In contrast, dihydroquinazolinone was afforded as the sole product when R is an ethyl group due to the more facile deprotonation of the associated NCR (see the SI for details)..
  20. (a) L. Legnani and B. Morandi, Angew. Chem., Int. Ed., 2016, 55, 2248–2251 CrossRef CAS; (b) L. Legnani, G. Prina-Cerai, T. Delcaillau, S. Willems and B. Morandi, Science, 2018, 362, 434–439 CrossRef CAS; (c) S. Chatterjee, I. Harden, G. Bistoni, R. G. Castillo, S. Chabbra, M. van Gastel, A. Schnegg, E. Bill, J. A. Birrell, B. Morandi, F. Neese and S. DeBeer, J. Am. Chem. Soc., 2022, 144, 2637–2656 CrossRef CAS; (d) Y. Zhou, J. Ni, Z. Lyu, Y. Li, T. Wang and G.-J. Cheng, ACS Catal., 2023, 13, 1863–1874 CrossRef CAS; (e) Y. Liu, Y. Chen, Y.-J. Zhao, G.-Q. Zhang, Y. Zheng, P. Yu, P. Chen and Z.-J. Jia, J. Am. Chem. Soc., 2024, 146, 24863–24870 CrossRef CAS.

This journal is © The Royal Society of Chemistry 2025
Click here to see how this site uses Cookies. View our privacy policy here.